Project Grant K99NS138387
- This $4,039,366 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), will support a research project titled "A Fully Humanized Functional Genomic Screen to Identify and Validate Pain Therapeutic Targets" under the NIH's Drug Use and Addiction Research Programs (CFDA 93.279). The project will leverage innovative CRISPR-based screening and human dorsal root ganglion (DRG) transcriptomic data to...
- This federal Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279), is focused on developing novel methods for selectively stimulating nociceptors (pain receptors) and measuring the brain's nociceptive-specific response in both healthy individuals and those with the chronic pain condition fibromyalgia. The $2,314,276 award to Emory University will fund the creation of a new...
- This $453,104 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports research to explore independent ascending spinal pain circuits that transmit pain signals to the brain. The primary focus is on understanding the role of a newly identified subset of spinal projection neurons expressing the GPR83 neuropeptide receptor, in...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $444,125 in funding to Duke University to explore the role of the LRRC55 regulatory protein in pain pathways. The key objectives are to: 1) delineate LRRC55's function in chronic pain behaviors using genetically-modified mice, 2) quantify changes in LRRC55 expression in dorsal root ganglion and spinal cord neurons...
- This $2,249,392 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research to validate senescent cells as a target for the treatment of chronic pain in aging. The project aims to rigorously characterize the role of senescent neurons and their senescence-associated secretory phenotype (SASP) in driving dorsal root ganglion hyperexcitability and persistent pain following...
- This $239,052 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to characterize the role of orexinergic projections from the hypothalamus to the spinal cord and their contribution to chronic pain. The research aims to apply physiological and behavioral approaches to probe the functional consequences of orexin peptides on...
- This federal Project Grant award of $446,875 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will fund research to generate and characterize a novel NTRK3-FLPO mouse line. The goal is to utilize this new mouse model in an intersectional genetic strategy to specifically access and manipulate the AB nociceptor population, an important type of primary sensory neuron that...
- This $764,659 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program supports research to investigate the mechanisms underlying neuropathic spontaneous pain. The key objectives are to characterize the role of local vascular movement in triggering neuropathic spontaneous pain, determine how mechanoreceptors in sensory neurons contribute...
- This federal Project Grant award of $597,999.00 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to investigate the neuronal populations and central sensitization mechanisms underlying mechanical allodynia (a condition where normally innocuous touch becomes painful after injury) in the dorsal horn. The research aims to identify the excitatory...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $246,750 to The Trustees of Columbia University in the City of New York, Health Sciences Division, to research the role of the mesocortical glutamatergic pathway in the development and maintenance of chronic neuropathic pain. The project aims to use in vivo imaging,...
This federal Project Grant award of $222,758 from the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), is funding research to map the functional roles of different neuron types in the dorsal root ganglia (DRG) and understand their contributions to pain perception in the brain. The primary awardee, the University of North Carolina at Chapel Hill (UNC-CH), will use innovative optogenetic and chemogenetic techniques to selectively inhibit distinct classes of DRG neurons and assess their impact on pain-related neuronal activity in the brain. This comprehensive functional mapping of DRG neuron types aims to advance the understanding of how specific peripheral sensory signals are processed and represented in the central nervous system, with the goal of identifying new targets for chronic pain interventions. The project is funded under the NIH's Drug Use and Addiction Research Programs (CFDA 93.279) and will be conducted over a 2-year period from August 2025 to July 2027.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $222.8k | 8/6/25 |